A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube
Hepatitis C

Kim Hunter shares her experience with hepatitis C.


Luz Lugo, MD, explains the importance of hepatitis C testing.
en español

What if I’m using illicit drugs or alcohol?

Hepatitis C and HIV are much more common among people who use drugs and alcohol than the general population. Some doctors may refuse, or be reluctant to treat, people who are using illicit drugs and alcohol—even when they need treatment and are ready and willing to undergo therapy.

Illicit Drug Use

Several studies have reported that illicit drug users can be safely and effectively treated for hepatitis C; in fact, cure rates are similar to those of nonusers. Comprehensive care and treatment seems to be the most effective route for people who are using drugs, because it provides them with access to both medical and mental health care, peer support, harm reduction services and addiction treatment.

HCV treatment decisions for people who are using illicit drugs should be made on an individual basis. All illicit drugs are not the same, and neither are all illicit drug users. Some can easily manage HCV treatment, while others may choose to wait until they feel more stable (see the next section, “What If I’m Using Methadone or Buprenorphine?”).

Whether a person shows up for medical appointments may be a better gauge for who is likely to get through HCV treatment than whether or not that person is using illicit drugs.

Some doctors are concerned that injection drug users may be reinfected with hepatitis C after being cured. Although this has happened, it is not common, and medical providers can help injection drug users prevent reinfection by referring people to needle exchange programs and/or by prescribing syringes.

Alcohol Use

Alcohol blunts the immune responses to hepatitis C, which may be why heavy drinkers generally have higher hepatitis C viral loads than nondrinkers. Regular alcohol intake—especially more than four drinks per day for men, and more than two per day for women—is known to increase the rate and severity of liver damage in people with hepatitis C; it also increases the risk for liver cancer.

Studies have linked both lifetime and recent alcohol use to poorer HCV treatment outcomes. However, these studies used less effective treatment than the current standard of care, and adherence was not measured. A more recent study suggests that poor treatment adherence, not actual alcohol intake, may be lowering cure rates. In the meantime, many doctors will not treat drinkers until they are willing to enter alcohol addiction treatment, or until they have been abstinent for six months.

On the other hand, some doctors have reported that starting HCV treatment leads to other healthy behaviors, such as cutting down or eliminating alcohol intake. It’s important to find a doctor you are comfortable working with, and to decide if—and when—you want help to cut down or stop drinking.

A Word About Marijuana Use

Researchers have found that marijuana use can be harmful for people with hepatitis C. Daily marijuana use increases fat buildup in liver cells (steatosis), which can worsen liver scarring. Researchers have also found that daily marijuana users are more likely to have serious liver damage than occasional users or nonusers.

In contrast, one study reported that modest cannabis users were more likely to complete HCV treatment and to be cured by it than nonusers, because marijuana helped them manage treatment side effects.


back next

Last Revised: April 03, 2012

This content is written by the POZ and AIDSmeds editorial team. For more information, please visit our "About Us" page.

TREATMENT NEWS
Hepatitis C updates
Hep C Genotype 3 Treatment Results Same in HIV Coinfection

Waistlines Tied to Liver Stiffness in Women With Hep C

Women Spontaneously Clear Hep C Better Than Men

HIV/Hep B Coinfection Responds Very Well to Viread

Liver Cancer Deaths Double in Two Decades

Conditions Outside of AIDS Pose Significant Threat to People With HIV

HIV and Hepatitis C Coinfection Raises Cognitive Impairment Risk for Men

Hep C Protease Inhibitor Incivek Is Safe, Effective for HIV Coinfection

HIV Meds and Alcohol Not a Toxic Mix, Yet Many Skip Doses While Drinking

Multivitamins: More Not Better When HIV Meds are Being Used

Obesity Linked to Chronic Non-AIDS Health Problems in HIV+ People

HIV Therapy Helps Reduce Risk of Non-AIDS Illnesses

Sofosbuvir (GS-7977) Shows Promise in HIV/Hep C-Coinfected People

Black Women With HIV and Hep C Less Likely to Die of Liver-Related Disease

Interferon, High Blood Pressure May be Risk to Vision

CDC Officially Recommends One-Time Hep C Tests for All Baby Boomers

Despite ARV Therapy, HIV/Hep C Patients Face Increased Risk of Serious Liver Disease

Hep C Treatment Failure Can Still Mean Less Liver Inflammation

HIV/Hep C Coinfection and Each Virus by Itself Increase Hip Fracture Risk

1 in 4 Los Angeles Homeless Have Hep C

Hep B Prevalence in U.S. Is Double the CDC’s Estimate

Curative Hep C Treatment Benefits Non-Liver Health and Survival in HIV

CDC Set to Recommend One-Time Hep C Tests for All Baby Boomers

Hep C Risk Highest for Baby Boomers, but Most Haven’t Been Tested

Depression Is Common and Needs Managing Before and During Hep C Interferon Treatment

Risk of Liver-Related Deaths Twice as High With Chronic Hep B Versus Hep C

Facebook to Promote Organ Donation; May Benefit People With Hep C or HIV

FDA to Docs: Best to Avoid Victrelis With Norvir-Boosted HIV Protease Inhibitors

Revised U.S. Guidelines Make Key HIV and Hep C Treatment Recs

Clearing or Curing Acute HCV Does Not Protect Against Reinfection

HCV Testing, Diagnosis Being Overlooked in People With HIV

Marker of Active Hep B Infection Declines in Those Coinfected with HIV, Treated with Tenofovir

ARV Liver Toxicity in HIV/Hep C Coinfected Patients on the Decline

Treating HIV During Pregnancy Also Lowers Risk of Transmitting Hep C to Baby

Incivek, Victrelis Studies Hint at Superior Cure Rates in HIV/HCV Coinfection

Hep C Now Trumps HIV as Cause of Death in U.S.

Merck Warns of Victrelis and HIV Protease Inhibitor Interactions

Many at Risk for Hep B in U.S. Aren't Getting Vaccinated

Experts Issue Early Guide for Hep C Protease Inhibitor Therapy in People Living with HIV

Chronic Hep B Doubles Risk of AIDS Illnesses and Death in People Living With HIV

Victrelis Keeps Hep C Viral Load Undetectable for 24 Weeks in 7 of 10 Coinfected Patients

Despite High CD4s, Unchecked Viral Load Linked to Higher AIDS Risk

Hepatitis C Medication Adherence Is an Important Challenge, Study Shows

New Hep C Treatment Guidelines Spell Out Incivek and Victrelis Use

Hepatitis C in the U.S. May Be Underestimated by Over a Million

BMS Drug Boosts Hep C Cure Rates

Coffee Helps Minimize Hepatitis C Treatment Side Effects

HIV Linked to False Negative Hep C Results Using Some Rapid Assays

DRACO: A Broad-Spectrum Therapy Against Multiple Viruses

Doubled Risk of Death Among Publicly Insured People With HIV in U.S.

Counseling, Drug Treatment Can Increase Hep C Treatment Eligibility

WHO World Hepatitis Day Report: One in 12 Living With Chronic Hep B or C

Hepatitis C Sexually Transmitted between HIV-Positive Men

HIV, Hep C Drug Development Pipeline is 'Robust,' Says Report

Survey Finds Support for Universal Hep C Testing

Liver Damage Increases Tenofovir-Induced Kidney Impairment Risk


> More Treatment News

Search for news stories about this topic

Lesson Index
Collapse All | Up One Level

TALK TO US
Tell us what you think
Poll
Have you visited your health care provider within the last 4 months?
Yes
No


Survey
HIV and Hepatitis C

more surveys
[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.